Really? When the price target is 8 times that? Admittedly old numbers, but every penny at this price is 3%. No reason to get excited until it breaks a buck.
Here's just the first paragraph:
"SAN FRANCISCO--(BUSINESS WIRE)-- Solazyme, Inc.(SZYM) , a renewable oil and ingredients company, is pleased to announce that the US Food and Drug Administration (FDA) has issued a favorable response to Solazyme’s notification concluding that Whole Algal Protein is Generally Recognized as Safe (GRAS) as an ingredient in food and beverage products. This No Questions letter will further pave the way for mainstream adoption of this new source of vegan protein enabling the creation of new products that meet consumer demand for healthy, sustainable ingredients."
If you don't agree with the analyst, look at this as a buying opportunity. People make money by buying when consensus is sell and by selling when consensus is buy. Do you believe the new target is based on faulty data analysis? Then your course of action is clear.
Shorts are training the longs. Based on trends, longs are now trained to sell at any time share price moves up a couple of percent. Longs are now doing the shorts work and the longer it continues, the easier it will be to short MNKD for a short term profit.
Don't think that this is a game changer, but it does show steady progress. With the increased cost of hospitalization and surgery, you want to be sure you're getting the care you need and no more. I'm seeing more and more preemptive surgeries being conducted in part due to the decisions made by some celebrities (hello, Angelina Jolie). Hopefully ROSG's and other companies in personalized medicine will change that trend.
I just heard that Pr. Obama is going to veto the Keystone Pipeline project. Does that make sense from an environmental perspective? It is OK to ship oil via tanker all over the world, but a pipeline that can be maintained on a continuous basis is an environmental threat?
It doesn't even make any sense from a political point of view. The more oil we get from friendly neighbors, the less we need from unfriendly nations.
Obviously to fund pipeline until products hit the market in 5 years. Better to issue the secondary before you really need the money.
Not sure of why your response got a thumbs down. As far as I'm concerned, anyone who supplies hard information gets a thumbs up. Those who write nothing more than "buy, buy, buy" or "sell, sell, sell" get a thumbs down. They add zero value.
Of course this turd is going to close at 7 +/- 5 cents. It is weekly options Friday. Sell the put and call for a net 20 cents and you'll be ahead as long as the price closes between 6.80 and 7.20. Sorry, but I'm rapidly coming to the conclusion that there are too few investors and far too many traders, especially in smaller cap, high volume stocks like CLF.
As far as I'm concerned, it isn't about the next quarter. 3-D printing is a technology that will grow at a pace faster than other types of technology in the coming years. I think it will model the past growth of digital cameras on-line retailing, and social media. DDD is among the leaders in this sector if share price drops on whatever short term news this quarter, I'll consider it an opportunity to build a position.
In the last month ROSG has issued several PRs that indicate good things from revenue standpoint are just around the corner. The question I have is whether there's enough cash to get us to the corner. It would seem that others feel the same way, with share lingering around 3. Implication is that another secondary will come out and until the price and dilution becomes public, caution is the key.
I'm just speculating. Until there is significant cash flow, even if not enough to continue funding of operations, share price will have a tough time getting back to the massive secondary we had at 5.
Ironic that he takes pride in saving one of the biggest sources of CO2 production: GM. While he's touring the US, wouldn't you like to see him at a coal fired power plant or coal mine?
Wow, there's some insight. Valuation on the basis of sales? On that basis, valuation should be zero for every development stage biotech that has yet to put a product on the market.
As for a merger, I'll vote against any offer that is shy of 5 times current value. Selling now would be selling at the bottom for all intents. Sure we had a good day yesterday, but valuation is still less than 2% of the IPO several years ago. It is barely above the massive $5 secondary of 2013.
Put your money where mouth is and buy some of those 6 calls expiring today. Certainly investing 5 cents to make a dollar is an acceptable 6 hour return.
OK, sounds good. However, wouldn't we prefeer to read "cash flow positive in 2017?" The implication is that they won't have to sell any more shares for about 2 years (other than what they've already contracted to sell.)
Nice to see 100+% increase in revenue, but even with that they haven't captured 1% of the market for their diagnostic tests. How long does it take to get 10% of the market? If sales continue to double every year, it'll take about 4 years to get it to $16 million. I'm patient, but not that patient.
You would think that a strong jobs report and the implication that interest rates will go up would be good for housing. More people at work and though rates may go a bit higher, they are still at multi-year lows. Clearly I'm confused and missing something.